Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UCN | ISIN: CA4576377002 | Ticker-Symbol: MWG
Tradegate
03.07.25 | 12:41
2,500 Euro
+1,63 % +0,040
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INMED PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
INMED PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4202,48019:02
2,4202,48004.07.

Aktuelle News zur INMED PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INMED PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.06.InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules213Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...
► Artikel lesen
25.06.InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules154Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...
► Artikel lesen
24.06.InMed Pharmaceuticals Inc. - 8-K, Current Report2
24.06.InMed stock soars after promising Alzheimer's drug preclinical results5
24.06.Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge3
24.06.InMed's Alzheimer's drug candidate shows reduced inflammation in lab tests11
24.06.InMed Pharmaceuticals: InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study269Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1ß, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor...
► Artikel lesen
13.06.InMed Pharmaceuticals: InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA891Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...
► Artikel lesen
13.06.InMed Pharmaceuticals Inc. - 8-K, Current Report1
13.05.InMed Pharmaceuticals Inc. - 8-K, Current Report6
13.05.InMed Pharmaceuticals Non-GAAP EPS of -$1.94, revenue of $1.26M4
13.05.InMed Pharmaceuticals: InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update477Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...
► Artikel lesen
12.05.InMed Pharmaceuticals Inc. - 10-Q, Quarterly Report3
25.04.InMed Pharmaceuticals Inc. - 8-K, Current Report2
13.02.InMed Pharmaceuticals Inc. - 8-K, Current Report-
13.02.InMed Pharmaceuticals GAAP EPS of -$3.64, revenue of $1.11M5
13.02.InMed Pharmaceuticals: InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update578Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of...
► Artikel lesen
12.02.InMed Pharmaceuticals Inc. - 10-Q, Quarterly Report-
03.02.InMed Pharmaceuticals Inc. - 8-K, Current Report1
03.02.InMed erzielt Fortschritte bei AMD-Behandlung mit vielversprechender IVT-Wirkstoffformulierung1
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1